R
Rarecells
Develops and commercializes the ISET technology to isolate circulating cancer cells for early cancer diagnosis and medical research
About Rarecells
Rarecells is a pioneering company in the field of early cancer detection, leveraging advanced DNA sequencing and artificial intelligence to identify circulating tumor cells (CTCs) at very early stages. The company serves healthcare providers, researchers, and patients who are at risk or already diagnosed with cancer. Operating in the global healthcare and biotechnology market, Rarecells employs a business model centered around the development and commercialization of non-invasive diagnostic tests. These tests are designed to detect cancer early, thereby improving treatment outcomes and potentially saving millions of lives. Revenue is generated through the sale of diagnostic devices, test kits, and associated services. The company's innovative approach includes the use of a specialized device that enriches CTCs from blood samples, making it easier to detect cancer cells early on. This technology is particularly beneficial for high-risk populations, such as heavy smokers, and aims to provide efficient screening solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Paris, France
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Core AI, Health Diagnostics, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Woman Founder
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $13M | $52M | Undisclosed | ↗ |
| GRANT✓Other financing | Dec 2018 | $231K | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Rarecells is 100 monthly website visits, down 95.5% over the last three months. Rarecells's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors4 additional known investors
Paris-Cité University
Assistance Publique - Hôpitaux de Paris
INSERM
University Paris René Descartes - Paris V
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rarecells on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rarecells’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.